Searchable abstracts of presentations at key conferences in endocrinology

ea0049s13.3 | Challenging pituitary diseases | ECE2017

Imaging of sellar masses

Buchfelder Michael

To date, magnetic resonance tomography is generally considered the imaging method of choice for its premium resolution of lesions and surrounding anatomic structures. This is mainly due to the improved soft tissue contrast this method offers. Other advantages are the possibility of direct multiplanar imaging in sagittal, coronal, and axial orientations and the avoidance of ionizing radiation. The goal of all imaging studies in this region is to indicate precisely the location,...

ea0032s2.2 | Cushing's Disease with negative pituitary imaging | ECE2013

Surgical approach to corticotroph adenomas poorly visible at preoperative imaging

Buchfelder Michael

Most pituitary operations for Cushings’s disease are technically difficult procedures. Since the souce of excessive ACTH-secretion in Cushing’s disesase is almost invariably a pituitary microadenoma, selective resection of this minute tumor is considered the primary standard therapy. However, almost half of the tumors escape direct preoperative detection even by sophisticated magnetic resonance imaging. Thus, in these the indication for surgery is based on laboratory...

ea0035p220 | Clinical case reports Pituitary/Adrenal | ECE2014

Neuropsychiatric aspects in a rare case of hypothalamic obesity

Stieg Mareike R , Buchfelder Michael , Stalla Gunter K

A 22-year-old woman presented with weight gain (class I obesity), oligomenorrhea, impaired vision, and altered concentration. With suspected craniopharyngeoma she was treated with transcranial surgery; in fact for a suprasellar haemangioma. Post-operatively, she still presented an alteration in appetite with hyperphagia and excessive weight gain up to class III obesity. This syndrome is described as ‘hypothalamic obesity’ and results from any damage to the ventromedi...

ea0029p1425 | Pituitary Clinical | ICEECE2012

Effects of medical treatment on proliferation parameters MIB-1 and topoisomerase-IIα in GH secreting pituitary adenomas

Schlaffer S. , Lin F. , Saeger W. , Buchfelder M.

Introduction: In this present study, we assessed the effects of the last preoperative medical treatment (dopamine-agonists, somatostatin-analogous and GH receptor antagonists) on the proliferation parameters Ki-67 and Topoisomerase-IIα in pituitary adenomas of patients with acromegaly.Material and methods:: We retrospectively studied the clinical characteristics, neuroimaging, histology and immuno-histochemistry (Ki-67 and topoisomerase-IIα lab...

ea0016p472 | Neuroendocrinology | ECE2008

Somatotropin release inhibiting factor (SRIF) downregulates Wnt/ß-catenin pathway in ACTH-secreting pituitary cell line AtT-20

Khattak Muhammad Nasir Khan , Kremenevskaya Natalia , Buchfelder Michael

Introduction: The involvement of the Wnt/ß-catenin pathway is apparent different epithelial human cancers. Wnt stabilizes ß-catenin (free ß-catenin) by preventing its phosphorylation which targets ß-catenin for degradation. Free ß-catenin is translocated to the nucleus where it stimulates a number of genes that modulate proliferation and differentiation upon binding to TCF/LEF-1. We have previously shown that Wnt/ß-catenin pathway is dysregulated ...

ea0013p231 | Neuroendocrinology and behaviour (including pituitary) | SFEBES2007

A prospective longitudinal study of anterior pituitary dysfunction following traumatic brain injury

Kleindienst Andrea , Weigel Daniel , Bock Christoph , Buchfelder Michael , Brabant Georg

Purpose: Neuroendocrine dysfunction represents a frequent consequence of traumatic brain injury (TBI) but has not been studied longitudinally as yet. Here we attempt to identify predictors of late endocrine insufficiency following TBI.Methods: 71 consecutive patients (age 18 – 87 yrs) with TBI assessed by an intial CT and the Glasgow Coma Score (GCS) were prospectively studied as to their pituitary function on day 0, 3 and 7 and dynamically 24–...

ea0011p518 | Endocrine tumours and neoplasia | ECE2006

Biochemical characteristics of ‘silent’ ACTH-secreting pituitary adenomas: Preoperative serum and urine hormone studies

Maser-Gluth C , Artlich G , Gutenberg A , Buchfelder M

‘Silent’ ACTH-secreting pituitary adenomas are not characterized by specific clinical features that would suggest the presence of hypercortisolism. In contrast, they present as non-functioning pituitary macroadenomas with either visual compromise or hypercortisolism. However, immunostaining reveals ACTH-secreting cells.In order to characterize the laboratory features of these tumours, we have preoperatively assessed 56 patients with either clin...

ea0041oc9.5 | Endocrine Tumours | ECE2016

Pituicytoma: a neuropathological analysis of 10 samples

Mende Klaus Christian , Matschke Jakob , Buslei Rolf , Buchfelder Michael , Fahlbusch Rudolf , Saeger Wolfgang , Flitsch Joerg

Introduction: Pituicytoma is a rare neoplasm of the sellar region, believed to originate from neurohypophyseal cells. Tumor resection is the primary treatment option, but may remain incomplete due to excessive bleeding of the well vascluarized tumor stroma. Therefore the search for alternative or additional treatment regimens is necessary. In a previous publication in 2012 the presence of VEGF-R was shown in one tumor sample, potentially opening the door for modern treatment o...

ea0041gp119 | Neuroendocrinology | ECE2016

Hypoxia-inducible factor 1α triggers growth hormone synthesis in acromegalic tumors

Lucia Kristin , Monteserin-Garcia Jose , Buchfelder Michael , Renner Ulrich , Stalla Gunter , Theodoropoulou Marily

Acromegaly is caused by excessive growth hormone (GH) secretion frequently due to GH-secreting pituitary tumors. Acromegalic tumors (ACRO) display reduced microvascular density versus normal pituitaries, suggesting they are under hypoxic conditions. Under hypoxia, tumors gain a survival advantage by stabilizing the transcription factor known as hypoxia-inducible factor 1 alpha (HIF1a). Western blot screening of ACRO (n=40) revealed significantly higher HIF1a protein l...

ea0041ep860 | Pituitary - Basic | ECE2016

Evidence for better response to somatostatin analogues in acromegalic patients treated with metformin

Winkelmann Moritz , Geraedts Victor , Lucia Kristin , Stormann Sylvere , Buchfelder Michael , Stalla Gunter , Theodoropoulou Marily

Somatostatin analogues (SSA) are the mainstay of pituitary-targeted pharmacological treatment in acromegaly, but are characterized by high incidence of resistance in half of cases. The successful management of acromegaly involves in addition to targeting biochemical control the treatment of the metabolic comorbidities and hypopituitarism. In this study we analysed the impact of the concomitant antidiabetic treatment and hormone replacement on the response to SSA. Data were col...